ストックスクリーナーアプリを入手
11.00
0.82%
0.09
プレマーケット:
11.15
0.15
+1.36%
Climb Bio Inc (CLYM) 最新ニュース
Climb Bio to share antibody trial data at European renal congress - Stock Titan
Climb Bio Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentOpen Trading Community - Newser
Climb Bio teases key Budoprutug, CLYM116 readouts at BioConnect - MSN
Climb Bio Inc. (CLYM) Surges Over 3% – Approaching Key Resistance ZoneTrending Momentum Stocks - newser.com
Climb Bio, Inc. drives new focus on APRIL-targeted B cell therapies at Dallas workshop - Traders Union
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect - sharewise.com
Climb Bio, Inc.Common Stock (CLYM) Stock Price, News, Quote & History - FinancialContent
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Climb Bio (CLYM) and Boston Scientific (BSX) - The Globe and Mail
Climb Bio (CLYM) Stock Price, News & Analysis - MarketBeat
Raymond James Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo
Piper Sandler reiterates Climb Bio stock rating on IgAN opportunity By Investing.com - Investing.com Nigeria
Climb Bio, Inc. participates in HC Wainwright fireside chat to outline strategic direction - Traders Union
CLYM: Multiple clinical data readouts in 2024 will shape pivotal study plans and market positioning - TradingView
Piper Sandler reiterates Climb Bio stock rating on IgAN opportunity - Investing.com
Piper Sandler Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Climb Bio (CLYM) price target increased by 18.34% to 19.62 - MSN
Climb Bio (CLYM) Q1 2026 Earnings: Why the Beat MattersFree Market Insights - Newser
Number of shareholders of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress - The Manila Times
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 ... - Caledonian Record
New immune thrombocytopenia antibody data headed to EHA 2026 - Stock Titan
H.C. Wainwright raises Climb Bio stock price target on trial progress - Investing.com Nigeria
Climb Bio to Present at Upcoming Investor Conferences - markets.businessinsider.com
H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $20 - Moomoo
H.C. Wainwright raises Climb Bio stock price target on trial progress By Investing.com - Investing.com South Africa
Biotech Climb Bio plans May and June investor talks online - Stock Titan
TradingKey - TradingKey
Climb Bio (CLYM) price target increased by 34.43% to 15.67 - MSN
Climb Bio (NASDAQ:CLYM) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Wedbush Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Budo judo moves aplenty for Climb in autoimmune - BioWorld News
Baird Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $21 - Moomoo
Climb Bio, Inc. 1Q 2026: Net income $(13.7M), EPS $(0.20) — 10-Q Summary - TradingView
Climb Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Climb Bio (NASDAQ: CLYM) trims Q1 2026 loss and raises $110M to fund pipeline - Stock Titan
[8-K] Climb Bio, Inc. Reports Material Event - Stock Titan
$110M financing gives Climb Bio room for multiple 2026 drug data readouts - Stock Titan
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates - marketscreener.com
A Quick Look at Today's Ratings for Climb Bio(CLYM.US), With a Forecast Between $19 to $22 - Moomoo
Wedbush Adjusts Price Target on Climb Bio to $15 From $14, Maintains Outperform Rating - Moomoo
Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo
Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLE - Yahoo Finance
Climb Bio Secures 110 Million Dollars Through Private Stock Placement - HarianBasis.co
Climb Bio reports B-cell depletion data for budoprutug trial By Investing.com - Investing.com South Africa
Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing - Insider Monkey
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):